BioCentury on BioBusiness,
Testing the tech transfer model
Monday, August 27, 2001
TaiGen Biotechnology Co. Ltd.'s financing and technology deal with Arena Pharmaceuticals Inc. demonstrates the power of personal relationships as well as providing the most high-profile milestone in the effort to build a fledgling biotechnology sector in Taiwan. Now what remains to be seen is whether the $37 million start-up deal will provide a successful proof of principle for the technology transfer model for industrial development.
TaiGen is launching operations with the series A financing also announced last week, with the investors including MPM Capital; Development Fund; Yuen Foo Yoong; China Development Industrial Bank; Shingkong Life Insurance; Yao Hwa Glass; Industrial Bank of Taiwan; Hotung Ventures; Cheng Xin Technology Development; China Synthetic Rubber; Fujisawa; Chailease Finance; Champion Venture; and Cathay Life Insurance.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]